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Abstract. Glioblastoma (GBM) is the most common and
aggressive primary brain tumor. The identification of novel
molecular prognostic markers of GBM has recently been an
area of great interest in neuro-oncology. The methylation
status of the MGMT gene promoter is currently a promising
molecular prognostic marker, but some controversial data have
precluded its clinical use. We analyzed MGMT methylation
by methylation-specific PCR in 90 GBM patients from four
Portuguese hospitals, uniformly treated with radiotherapy
combined with concomitant and adjuvant temozolomide
(Stupp protocol). The Kaplan-Meier method was used to
construct survival curves, and the log-rank test and a Cox-
regression model were used to analyze patient survival. The
methylation status of MGMT was successfully determined in
89% (80/90) of the tumors. The frequency of tumoral MGMT
promoter methylation was 47.5%. The median overall
survivals (OSs) were 16 months (95% CI 12.2-19.8) and 13
months (95% CI 13.3-18.7) for patients whose tumors had a
methylated or unmethylated MGMT, respectively. Univariate
and multivariate analyses did not show any statistically
significant association between MGMT methylation status
and patient OS (P=0.583 by the log-rank test; P=0.617 by the
Cox-regression test) or progression-free survival (P=0.775 by
the log-rank test; P=0.691 by the Cox-regression test). None
of the patient clinical features were significantly correlated
with survival. This is the first study to report the frequency of
MGMT methylation among Portuguese GBM patients. Our
data did not show statistically significant associations between
MGMT promoter methylation and the outcome of GBM
patients treated with temozolomide. Additional robust
prospective studies are warranted to clarify whether the
MGMT status should be used in clinical decisions.
Introduction
Tumors of the central nervous system account for a small
percentage of all types of human tumors (1), but encompass a
wide variety of distinct disease entities (2). Data from the
GLOBOCAN 2002 database report an incidence of brain and
central nervous system tumors in Portugal of ~422 cases per
year in males and ~362 cases per year in females (3). Gliomas
are the most common primary brain tumors (2,4) and
encompass a wide variety of tumors thought to originate either
from stem cells, glial precursor cells or glial differentiated
cells. Astrocytomas are the major histological subtype,
accounting for ~75% of all gliomas (4), of which GBM
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(WHO grade IV) is by far the most common and malignant.
The highly infiltrative nature coupled with the high prolifer-
ative potential causes this tumor to be particularly devastating,
for which no curative therapies are currently available (5,6).
Two main subtypes of GBM can be distinguished based on
their clinical presentation: the most common subtype, primary
(or de novo) GBM, develops without the presence of any
precursor neoplastic lesion and manifests after a short clinical
history (usually less than 3 months); secondary GBMs are
much rarer and develop from lower grade tumors (2,7).
Despite recent improvements in therapeutic approaches,
treatment still remains mostly palliative, and GBM patients
usually present an extremely poor prognosis. The median
survival is typically reported to be ~12 months in clinical
trials (2), but a large population-based study in 2004 reported
a median survival for these patients of ~5 months, with only
~18% and ~3% of the patients surviving over 1 and 2 years,
respectively (8). The current paradigm of therapy for patients
with newly diagnosed GBM includes surgical resection
(when feasible), radiotherapy and chemotherapy. A phase III
trial by Stupp et al clearly showed that GBM patients treated
with radiotherapy combined with concomitant and adjuvant
temozolomide (TMZ, an orally administered alkylating
agent), also known as TMZ-based chemoradiation, had an
increased overall survival (OS) compared with patients treated
with radiotherapy alone (9), establishing a new standard in the
management of these tumors. Despite a significant improve-
ment, it is important to note that this treatment resulted in a
small difference in overall survival. In order to improve the
clinical outcome of these patients, it is widely acknowledged
that the ideal treatment of GBMs must be individualized, based
on the particular features of the tumor. Indeed, the prognosis of
these patients is quite variable and unpredictable. Some of
the most well-established prognostic markers in GBM
include patient clinical features, such as age, Karnofsky
performance status (KPS) (10) and extent of tumor resection;
however, these markers do not satisfactorily predict patient
outcome (11). One of the major goals of current neuro-
oncology research is to identify robust and clinically relevant
molecular markers that can add value to those more classic
clinical prognostic factors.
MGMT (O-6-methylguanine-DNA methyltransferase), a
gene located on chromosome 10q26, encodes a DNA-repair
enzyme that has been shown to contribute to the chemo-
resistance of GBM cells to alkylating agents (12). Specifically,
a landmark study by Hegi et al showed that GBM patients
whose tumors had a methylated MGMT promoter presented a
significantly longer median OS (21.7 months) and 2-year
survival rate (46%) when treated with TMZ-based chemo-
radiation compared with patients without MGMT promoter
methylation who were treated similarly (median survival of
12.7 months and 2-year survival rate of 13.8%) (13).
Additionally, in the data set of Hegi et al, MGMT promoter
methylation was an independent favorable prognostic factor,
irrespective of treatment. Due to its potential prognostic value,
the assessment of MGMT methylation status is currently a
common practice in clinical trials involving GBM patients
(14). Despite these striking findings, there is a significant
body of controversial data surrounding the reproducibility of
these results, questioning the true implication of MGMT as a
GBM prognostic marker and/or a specific predictor of TMZ-
based chemotherapy (15-17). In this context, we aimed to
assess the frequency and clarify the prognostic capacity of
MGMT promoter methylation in a set of Portuguese GBM
patients uniformly treated with TMZ-based chemoradiation.
Materials and methods
Human tumor samples. Human tumor samples were obtained
from primary GBM patients newly diagnosed according to
the WHO criteria (2) and surgically resected between 2004
and 2007 at 4 hospitals in northern Portugal: Hospital São
João (n=36), Hospital Pedro Hispano (n=33), Hospital Santo
António (n=11) and Hospital São Marcos (n=10). All patients
underwent radiotherapy plus continuous concomitant TMZ
after surgery, followed by maintenance cycles of TMZ,
according to the Stupp protocol (9). Extension of tumor
resection was assessed by the neurosurgeon and by post-
operative magnetic resonance imaging (MRI) and were
classified as gross resection (total or subtotal) or biopsy. The
clinicopathological features are summarized in Table I. All
procedures followed in this study were in accordance with
institutional ethical standards, and the biological samples
were unlinked and unidentified from their donors. Follow-up
data were available for all patients as of July 2008, and were
collected through direct interview with patients or their
relatives and by review of in-hospital patient files.
DNA isolation. DNA was isolated by macrodissection from
10-μm sections of formalin-fixed paraffin-embedded tumor
tissue samples, avoiding the harvesting of surrounding normal
brain tissue by comparing each slide with the corresponding
hematoxylin and eosin (H&E)-stained slide (marked for the
area of tumoral tissue) (18). The recovered tissues were
processed with the QIAamp® DNA Micro Kit (Qiagen)
following the manufacturer's instructions. DNA quality control
and yield were assessed by spectrophotometry using
Nanodrop™.
DNA bisulfite treatment and MGMT methylation-specific
PCR analysis. Genomic DNA was subjected to bisulfite
treatment using the EZ DNA Methylation-Gold™ Kit (Zymo
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Table I. Clinicopathological features of glioblastoma patients
treated with temozolomide-based chemoradiation (n=90).
–––––––––––––––––––––––––––––––––––––––––––––––––
Male/female ratio 1.9
Age, years (median ± SD) 56±11
Karnofsky performance score
≥80 (n) 48
<80 (n) 42
Extent of resection
Total or subtotal (n) 81
Biopsy (n) 9
–––––––––––––––––––––––––––––––––––––––––––––––––
n, number of patients.
–––––––––––––––––––––––––––––––––––––––––––––––––
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Research) following the manufacturer's instructions. The
promoter MGMT methylation-specific polymerase chain
reactions (MSP) were performed using a two-step nested
approach, and the results were confirmed by one-step MSP in
a subset of tumors as previously described (13,19). Peripheral
blood DNA from tumor-free controls and CpGenome™
Universal Methylated DNA (Chemicon International) were
used as MGMT unmethylated and methylated controls,
respectively. The PCR products were resolved on 4% low-
melting point agarose gels. Analysis of MSP data was
performed by investigators who were blind to the clinical
data.
Statistical analyses. The Kaplan-Meier method was used to
estimate OS and progression-free survival (PFS), and the log-
rank test was used to assess the differences. OS was measured
from the time of surgical resection to patient death, or the last
date when the patient was known to be alive. PFS time was
defined as the time from surgical resection to the time of
demonstrated tumor growth on follow-up imaging, or evidence
of neurological decline. Multivariate survival analyses by use
of Cox proportional hazards models (backward selection)
were performed to adjust for the effects of potential
confounding factors, including patient age (used as a
continuous variable), gender, KPS and extent of tumor
resection. All statistical tests were two-sided, and
significance was considered at values of P<0.05. Data
analysis was performed using SPSS 16.0 software (SPSS,
Inc.).
Results
Patient clinical features which may have an effect on
prognosis, such as gender, age at diagnosis, KPS and extent
of tumor resection, are summarized in Table I. The tumoral
MGMT methylation status was successfully determined by
MSP in 80 tumor samples (89%), of which 38 GBMs (47.5%)
had a methylated MGMT promoter. Fig. 1 presents a typical
MSP analysis of the methylation status of the MGMT
promoter.
Considering the whole tumor set, independently of
clinical features or MGMT methylation status, the median OS
and PFS were 14 months (95% CI 11.5-16.5) and 9 months
(95% CI 7.5-10.5), respectively. The overall 2-year survival
rate was 16.7%. Table II summarizes the median OS and
median PFS of patients based on clinicopathological features
(gender, age, KPS and extent of tumor resection) and MGMT
methylation status. By using the log-rank test, no statistically
significant associations were detected between each individual
variable and GBM patient OS or PFS (P>0.05) (Table II).
Similarly, a multivariate Cox proportional model did not
show any statistically significant correlation between the
studied variables and GBM patient outcome (P>0.05) (Table II).
Nevertheless, patients whose tumors had a methylated MGMT
promoter showed a slightly improved median OS of 16 months
(95% CI 12.2-19.8) as compared to patients with an unmeth-
ylated MGMT promoter (13 months, 95% CI 11.1-14.9;
Fig. 2), but the differences were not statistically significant
(P=0.583 by the univariate test; P=0.617 by the multivariate
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Table II. Associations between clinical features or status of tumoral MGMT promoter methylation and prognosis of GBM
patients, assessed by univariate (log-rank test) and multivariate (Cox-regression) analyses.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Overall survival Progression-free survival
––––––––––––––––––––––––––––––––––––––– ––––––––––––––––––––––––––––––––––––––
Median (95% CI)a P-value P-value Median (95% CI)a P-value P-value
(Log-rank) (Cox) (Log-rank) (Cox)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gender
Males 14 (10.6-17.4) 9 (6.9-11.1)
Females 14 (11.6-16.4) 0.436 0.807 9 (5.9-12.1) 0.864 0.990
Ageb
>56 13 (9.5-16.5) 9 (6.9-11.1)
≤56 14 (11.0-17.0) 0.978 0.951 10 (8.0-12.0) 0.754 0.431
KPS
≥80 16 (14.2-17.8) 10 (7.2-12.8)
<80 12 (9.8-14.2) 0.165 0.311 8 (5.7-10.3) 0.096 0.125
Extent of resection
Total or subtotal 13 (10.4-15.6) 9 (7.5-10.5)
Biopsy 16 (13.3-18.7) 0.458 0.481 6 (1.1-10.9) 0.942 0.930
MGMT status
Methylated 16 (12.2-19.8) 9 (5.0-13.0)
Unmethylated 13 (11.1-14.9) 0.583 0.617 10 (8.1-12.0) 0.775 0.691
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aMedian survival and 95% confidence intervals, in months. bPatient age was used as a continuous variable for the Cox-regression model.
KPS, Karnofsky performance status.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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model; Table II). The median PFS was closely similar
between patients whose tumors had methylated (9 months,
95% CI 5.0-13.0) and unmethylated (10 months, 95% CI
8.1-12.0) MGMT promoter (P=0.775 by the log-rank test;
P=0.691 by the Cox model; Table II). The 2-year survival
rate was 15.8% and 16.7% in patients with methylated and
unmethylated MGMT, respectively (P=0.915).
Discussion
GBM is a particularly devastating disease as no curative
therapies are available, and very few well-established
prognostic factors have been identified. Many recent efforts
in the field of neuro-oncology are directed to developing
more efficient therapies, but only a small fraction of patients
experience significant clinical benefit and prolonged survival.
Despite the variability of the clinical responses, the majority of
patients with GBM are presently treated in a uniform
standardized way, following a ‘one fits all’ therapeutic
approach, regardless of the individual molecular characteristics
of each tumor that most likely affect patient prognosis.
Consequently, many patients display minor responses and
major therapy-related toxicities.
The recent introduction of radiotherapy plus concomitant
and adjuvant TMZ treatment for GBM has led to a small but
significant improvement in patient outcome (9); however, the
responses are still very poor and unpredictable. While the
EORTC-NCIC trial by Hegi et al (13) implicated the status
of MGMT promoter methylation as a biomarker of GBM
patient response to TMZ, all GBM patients continue to be
treated with TMZ, regardless of their MGMT status (13). To
note, the conclusions of Hegi et al were somewhat confounded
and questioned due to several limitations of the study. First,
the studies were performed retrospectively on a subset of
patients from whom adequate tumor tissue was available.
Second, although the difference in survival based on MGMT
methylation status was highly significant, more than half of
the methylated MGMT patients (with a predictably favorable
outcome) did not survive for 2 years, while ~15% of the
patients with unfavorable unmethylated MGMT did survive
over 2 years. Third, MGMT methylation was associated with
improved outcomes both in the temozolomide-based chemo-
radiation and radiation-only arms, suggesting that it may
partly be a prognostic marker associated with the nature of
the tumor, rather than a truly therapy-specific predictive
marker. Lastly, many of the patients in the radiation-only arm
also received TMZ at recurrence. Regardless, this was a
landmark study suggesting that methylation of MGMT is
both a prognostic marker and a specific marker of response to
TMZ in GBM patients. Indeed, the conclusions of Hegi et al
were recently corroborated by a 5-year analysis of the
EORTC-NCIC trial, where Stupp et al (20) confirmed that
the methylation of the MGMT promoter is associated with
better outcome and benefit from TMZ chemotherapy. The
first study implicating a correlation between MGMT levels
and survival of malignant glioma patients dates back to 1998,
when Jaeckle et al showed that patients treated with BCNU
(a nitrosourea used as a chemotherapeutic agent) whose
tumors had low or undetectable levels of MGMT had an
improved survival as compared to those whose tumors had
detectable MGMT activity (21). Soon after, Esteller et al
reported for the first time that methylation of the MGMT
gene promoter led to loss of MGMT expression in human
tumors in vivo (22). In 2000, Esteller et al found that a
methylated MGMT promoter in malignant glioma was
associated with improved overall and PFS, independently of
patient age and KPS (12). Mechanistically, the ability of
functional MGMT protein to remove the cytotoxic chemo-
therapy-induced alkyl groups from the O6-guanine of DNA,
and thus prevent killing of tumor cells, supported the clinical
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Figure 1. Methylation-specific PCR (MSP) analyses of the MGMT promoter
in glioblastoma tumor tissue from three patients (GBM 1, GBM 2 and GBM 3).
MSP control reactions consisted of blood-extracted DNA from a cancer-free
individual for use as the umethylated DNA control (Unm.), and a CpGenome
Universal Methylated DNA as the methylated DNA control (Met.). Note the
presence of bands in both the unmethylated (U, 93 bp) and methylated (M,
81 bp) lanes for glioblastoma samples 1 and 3, reflecting a methylated
MGMT promoter. The lack of a band in the lane corresponding to methyl-
ation-specific primers for glioblastoma sample 2 reflects the absence of
MGMT promoter methylation. PCR reactions in the absence of DNA (H2O)
were performed as negative controls for both the unmethylated and
methylated reactions. Figure 2. Kaplan-Meier analyses of the influence of MGMT promoter
methylation on overall survival of glioblastoma patients treated with
temozolomide-based chemoradiation. Patients whose tumors present a
methylated MGMT promoter (black curve) show a trend of improved overall
survival than patients whose tumors have an unmethylated MGMT promoter
(grey curve), but the differences did not reach statistical significance
(P=0.583 by the log-rank test; see text for details).
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Table III. Prognostic significance of MGMT methylation in glioblastoma reported in the literature.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Author (Reference) Year n Treatment Effect of MGMT
methylation on survivala
–––––––––––––––––––
PFS OS
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Esteller, et al (12) 2000 29 BCNU Yes Yes
Balana, et al (16) 2003 21 TMZ + cisplatin (n=7) NS ND
BCNU (n=7) Yes ND
No treatment (n=3) ND ND
Paz, et al (26) 2004 51 BCNU or CCNU or TMZ NS NS
Hegi, et al (27) 2004 38 Concomitant + adjuvant TMZ ND Yes
Blanc, et al (28) 2004 44 BCNU or fotemustine (n=2); radiation-only (n=14); 
Radiation + chemotherapy (BCNU or fomustine) (n=22); 
No treatment (n=6) NS NS
Kamiryo, et al (17) 2004 74 ACNU NS NS
Watanabe, et al (29) 2004 29 IAR regimen Yes Yes
Hegi, et alb (13) 2005 100 Radiotherapy only ND Yes
106 Concomitant + adjuvant TMZ Yes Yes
Brandes, et al (42) 2006 22 (recurrent GBMs) TMZ after recurrence NS NS
Herrlinger, et al (31) 2006 19 CCNU + TMZ Yes Yes
Piccirilli, et al (41) 2006 22 (≥80 years) Chemotherapy not specified ND Yes
Wick, et al (30) 2007 36 Alternating weekly TMZ NS NS
Eoli, et al (33) 2007 86 1st line cisplatin + BCNU; 
PCV or TMZ after recurrence Yes Yes
Criniere, et al (32) 2007 39 Concomitant + adjuvant nitrosureas ND Yes
38 Adjuvant nitrosureas ND NS
85 Radiotherapy only ND NS
Donson, et al (40) 2007 10 (pediatric GBM) TMZ (n=7) or etoposide (n=3) Yes Yes
Brandes, et al (45) 2008 103 Concomitant + adjuvant TMZ Yes Yes
Smith, et al (48) 2008 27 Gliadel wafers ND Yes
Murat, et al (39) 2008 42 Concomitant + adjuvant TMZ Yes Yes
Sijben, et al (50) 2008 29 (≥65 years) Concomitant + adjuvant TMZ NS NS
Gorlia, et alb (35) 2008 106 Concomitant + adjuvant TMZ ND Yes
Dunn, et al (44) 2009 109c Concomitant + adjuvant TMZ Yes Yes
Brandes, et al (23) 2009 37 (≥65 years) Concomitant + adjuvant TMZ Yes Yes
Clarke, et al (46) 2009 48 TMZ (metronomic versus dose-dense) NS NS
Wemmert, et al (36) 2009 27 TMZ after recurrence ND NS
Stupp, et alb (20) 2009 100 Radiotherapy only ND Yes
106 Concomitant + adjuvant TMZ Yes Yes
Glas, et al (38) 2009 23 CCNU + TMZ Yes Yes
Park, et al (47) 2009 48 ACNU + cisplatin ND NS
Prados, et al (37) 2009 44 Erlotinib + TMZ ND Yes
Sadones, et al (49) 2009 22 TMZ after recurrence NS NS
Schaich, et al (43) 2009 61 Concomitant + adjuvant TMZ NS NS
Sonoda, et al (25) 2009 30d ACNU Yes Yes
Mellai, et al (24) 2009 101 Not specified ND Yes/Noe
Metellus, et al (51) 2009 19 (recurrent GBMs) Carmustine wafers Yes Yes
Grossman, et al (52) 2009 29 Concomitant + adjuvant TMZ and talampanel Yes Yes
Martinez, et al (53) 2009 46f TMZ ND NS
Piperi, et al (54) 2009 17 Not specified ND Yesg
Weller, et al (55) 2009 63 Radiotherapy-only NS NS
183 Concomitant + adjuvant TMZ Yes Yes
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
n, number of patients; PFS, progression-free survival; OS, overall survival; NS, not significant; ND, not determined; ACNU, 3-[(4-amino-2-methyl-
5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride (nimustine); BCNU, 1,3-bis-(chloro-ethyl)-1-nitrosourea (carmustine, Gliadel);
CCNU, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (lomustine); IAR, IFN-ß, ACNU and radiotherapy; PCV, procarbazine, lomustine and
vincristine; TMZ, temozolomide. aOnly statistically significant results (P<0.05) are considered. bThese studies analyzed the same tumor set from the
EORTC-NCIC trial. cMGMT promoter was considered methylated by pyrosequencing when ≥9% of CpG dinucleotides were methylated. dThe set of
30 GBM patients in this study compared long-term and short-term survivors only. eStatistically significant by univariate analysis, but not significant
by multivariate analysis. fMGMT methylation status was determined by a microarray-based DNA methylation analysis. gPatients with a methylated
MGMT promoter had a significantly worse prognosis than unmethylated cases.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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finding that lack of MGMT expression was associated with
improved outcomes. Whether this molecular marker should
ultimately direct the treatment of newly diagnosed patients is
still a fundamental and controversial question. Much of the
controversy surrounding the prognostic value of MGMT is
partly due to studies including very heterogeneous groups of
patients with different glioma subtypes and who underwent
different treatment regimens. In addition, not all studies
analyzed the MGMT status at the level of DNA methylation in
the promoter region by methylation-specific polymerase
chain reaction (MSP); some studies focused on mRNA
expression by RT-PCR and protein levels by immuno-
histochemistry and quantitative immunofluorescence (15).
Nevertheless, contradictory results are also reported even in
studies that evaluated the influence of MGMT promoter
methylation on the prognosis of patients with GBM (Table III)
(12,13,16,17,20,23-55).
In our study, we attempted to clarify whether MGMT
methylation is a biomarker of clinical outcome in GBM
patients treated with the recently introduced TMZ-based
chemoradiation protocol and how it compares to the
prognostic value of classic clinicopathological factors. By
studying a set of 90 GBM patients from northern Portugal,
we were unable to detect any significant correlations between
patient clinical features, MGMT methylation status and
prognosis. Other studies have also failed to show such
correlations (Table III). To note, the frequency of MGMT
promoter methylation in our data set is similar to the
previously reported frequencies (13,23,30,33,35,55).
Additionally, the median OS and median PFS in our set of
GBM patients are in line with other recently published
studies (20,23,55). Some possible limitations of our study
include the relatively small sample size, which may be a
limiting factor in achieving statistical significance, and the
fact that we analyzed a multicenter tumor set collected from
4 independent institutions. Nevertheless, our sample size
compares favorably with other similar studies published in
the literature (Table III); additionally, our population-based
study is likely to closely illustrate the difficulties in identifying
significant determinants of patient survival, as this type of
study is typically less controlled and more heterogeneous
than well-designed prospective clinical trials. Obviously, the
argument that MGMT methylation does not predict GBM
patient response to this therapeutic regimen is still equally
valid. It is also relevant to stress that the most appropriate
method to assess MGMT status in gliomas is quite contro-
versial. Validated and commercially available MGMT
methylation assays have not yet been approved for clinical use
and may indeed be technically challenging. In spite of a recent
report arguing in favor of the feasibility and reliability of
nested, gel-based methylation-specific PCR (MSP) analysis,
suggesting it could be routinely implemented in the clinical
setting (56), the use of MSP is often considered not to be so
straightforward (57-60). Its use has raised some concerns due
to inter- and intra-test variability and sensitivity and specificity
issues (57,59). One recent report argues that a quantitative
MSP test for MGMT methylation is more specific than
conventional gel-based MSP (61). Furthermore, MGMT
silencing can occur through methylation of specific cytosines
within the CpG island (62); thus, it is important to determine
which CpG dinucleotides are the most predictive of potential
MGMT silencing. A recent study using pyrosequencing
methylation analysis argues that a new set of CpG dinucleo-
tides in the MGMT promoter CpG island is more robust in
predicting gene silencing than those classically tested by the
MSP assay (63). Conceptually, while a methylated MGMT
promoter precludes gene expression, the absence of such
methylation does not necessarily translate into activation of
gene expression, as specific transcription factors [e.g., Sp1
(64) and TP53 (65)], permissive chromatin states (64,66-69),
and absence of negative transcriptional regulators (e.g., IFN-ß)
are also required. Additionally, it is reasonable to assume
that, given the heterogeneity of MGMT expression within
individual tumors, a fraction of the cells within the entire
tumor load may lack MGMT expression, despite an
unmethylated MGMT status, and may therefore be sensitive
to temozolomide. A recent study also suggests that variation
in MGMT promoter methylation can occur within the same
tumor after treatment (70), stressing that clinical decisions
based on MGMT require caution. Despite these consider-
ations as well as the consensual belief that additional
molecular markers of GBM patient outcome are important in
determining the tumor response to therapy, if the relevance of
MGMT promoter methylation status in GBM is corroborated
by an ongoing phase III large study by the Radiation Therapy
Oncology Group (RTOG 0525), patients with unmethylated
MGMT promoter may be selected for alternative treatment
options in the future. Potential alternative strategies to
overcome MGMT-mediated chemoresistance include: (i) use
of temozolomide together with MGMT-inactivating drugs
(71,72) such as O6-benzylguanine (73,74) or inhibitors of
other DNA repair enzymes; and (ii) use of dose-intensive
temozolomide regimens (71) which deplete MGMT levels
more rapidly than lower doses (75).
In conclusion, our study is the first to report the frequency
of tumoral MGMT promoter methylation among Portuguese
GBM patients and to analyze the correlations between clinical
features, MGMT status and outcome in a set of patients
uniformly treated with concomitant and adjuvant TMZ
chemoradiation. In light of our data, together with the
controversies reported in the literature, further studies are
warranted to clarify the clinical prognostic relevance of
MGMT methylation in GBM.
Acknowledgements
This project was sponsored, in part, by Schering-Ploug
Farma (Portugal). B.M.C. and O.M. are recipients of
fellowships from the Portuguese Science and Technology
Foundation (SFRH/BPD/33612/2009 and SFRH/BD/36463/
2007). The funding institutions had no role in the study design,
data collection and analysis, interpretation of the results, the
preparation of the manuscript, or the decision to submit the
manuscript for publication.
References
1. Espey DK, Wu XC, Swan J, et al: Annual report to the nation
on the status of cancer, 1975-2004, featuring cancer in
American Indians and Alaska Natives. Cancer 110: 2119-2152,
2007.
COSTA et al:  MGMT PROMOTER METHYLATION AND OUTCOME OF GLIOBLASTOMA PATIENTS1660
1655-1662.qxd  23/4/2010  10:20 Ì  ™ÂÏ›‰·1660
2. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO
classification of tumours of the central nervous system. Acta
Neuropathol 114: 97-109, 2007.
3. Parkin DM, Bray F, Ferlay J, and Pisani P: Global cancer
statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
4. CBTRUS. Supplement Report: Primary Brain Tumors in the
United States. Central Brain Tumor Registry of the United
States, Hinsdale, IL, 2008
5. Franceschi E, Tosoni A, Bartolini S, Mazzocchi V, Fioravanti A,
and Brandes AA: Treatment options for recurrent glioblastoma:
pitfalls and future trends. Expert Rev Anticancer Ther 9: 613-619,
2009.
6. Reardon DA, Rich JN, Friedman HS, and Bigner DD: Recent
advances in the treatment of malignant astrocytoma. J Clin
Oncol 24: 1253-1265, 2006.
7. Ohgaki H and Kleihues P: Genetic pathways to primary and
secondary glioblastoma. Am J Pathol 170: 1445-1453, 2007.
8. Ohgaki H, Dessen P, Jourde B, et al: Genetic pathways to glio-
blastoma: a population-based study. Cancer Res 64: 6892-6899,
2004.
9. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N
Engl J Med 352: 987-996, 2005.
10. Curran WJ Jr, Scott CB, Horton J, et al: Recursive partitioning
analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 85:
704-710, 1993.
11. Rivera AL, Pelloski CE, Sulman E and Aldape K: Prognostic
and predictive markers in glioma and other neuroepithelial
tumors. Curr Probl Cancer 32: 97-123, 2008.
12. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of
the DNA-repair gene MGMT and the clinical tesponse of gliomas
to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
13. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing
and benefit from temozolomide in glioblastoma. N Engl J Med
352: 997-1003, 2005.
14. Clinical Trials with Glioblastoma Patients. http://clinicaltrials
gov/2009. January 7. Available from: URL: http://clinicaltrials.gov/
ct2/results?term=glioblastoma.
15. Brell M, Tortosa A, Verger E, et al: Prognostic significance of
O6-methylguanine-DNA methyltransferase determined by
promoter hypermethylation and immunohistochemical expression
in anaplastic gliomas. Clin Cancer Res 11: 5167-5174, 2005.
16. Balana C, Ramirez JL, Taron M, et al: O6-methyl-guanine-DNA
methyltransferase methylation in serum and tumor DNA
predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not
to temozolamide plus cisplatin in glioblastoma multiforme. Clin
Cancer Res 9: 1461-1468, 2003.
17. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M and
Ushio Y: Correlation between promoter hypermethylation of the
O6-methylguanine-deoxyribonucleic acid methyltransferase
gene and prognosis in patients with high-grade astrocytic
tumors treated with surgery, radiotherapy, and 1-(4-amino-2-
methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-
based chemotherapy. Neurosurgery 54: 349-357, 2004.
18. Basto D, Trovisco V, Lopes JM, et al: Mutation analysis of
B-RAF gene in human gliomas. Acta Neuropathol 109: 207-210,
2005.
19. Palmisano WA, Divine KK, Saccomanno G, et al: Predicting
lung cancer by detecting aberrant promoter methylation in
sputum. Cancer Res 60: 5954-5958, 2000.
20. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy
with concomitant and adjuvant temozolomide versus radio-
therapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial.
Lancet Oncol 10: 459-466, 2009.
21. Jaeckle KA, Eyre HJ, Townsend JJ, et al: Correlation of tumor
O6 methylguanine-DNA methyltransferase levels with survival
of malignant astrocytoma patients treated with bis-chloroethyl-
nitrosourea: a Southwest Oncology Group study. J Clin Oncol
16: 3310-3315, 1998.
22. Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG:
Inactivation of the DNA repair gene O6-methylguanine-DNA
methyltransferase by promoter hypermethylation is a common
event in primary human neoplasia. Cancer Res 59: 793-797,
1999.
23. Brandes AA, Franceschi E, Tosoni A, et al: Temozolomide
concomitant and adjuvant to radiotherapy in elderly patients
with glioblastoma: correlation with MGMT promoter methyl-
ation status. Cancer 115: 3512-3518, 2009.
24. Mellai M, Caldera V, Annovazzi L, et al: MGMT promoter
hypermethylation in a series of 104 glioblastomas. Cancer
Genomics Proteomics 6: 219-227, 2009.
25. Sonoda Y, Kumabe T, Watanabe M, et al: Long-term survivors
of glioblastoma: clinical features and molecular analysis. Acta
Neurochir 151: 1349-1358, 2009.
26. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al: CpG island hyper-
methylation of the DNA repair enzyme methyltransferase
predicts response to temozolomide in primary gliomas. Clin
Cancer Res 10: 4933-4938, 2004.
27. Hegi ME, Diserens AC, Godard S, et al: Clinical trial substantiates
the predictive value of O-6-methylguanine-DNA methyl-
transferase promoter methylation in glioblastoma patients treated
with temozolomide. Clin Cancer Res 10: 1871-1874, 2004.
28. Blanc JL, Wager M, Guilhot J, et al: Correlation of clinical
features and methylation status of MGMT gene promoter in
glioblastomas. J Neurooncol 68: 275-283, 2004.
29. Watanabe T, Katayama Y, Komine C, et al: O6-methylguanine-
DNA methyltransferase methylation and TP53 mutation in
malignant astrocytomas and their relationships with clinical
course. Int J Cancer 113: 581-587, 2005.
30. Wick A, Felsberg J, Steinbach JP, et al: Efficacy and tolerability
of temozolomide in an alternating weekly regimen in patients
with recurrent glioma. J Clin Oncol 25: 3357-3361, 2007.
31. Herrlinger U, Rieger J, Koch D, et al: Phase II trial of Lomustine
plus temozolomide chemotherapy in addition to radiotherapy in
newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24:
4412-4417, 2006.
32. Criniere E, Kaloshi G, Laigle-Donadey F, et al: MGMT
prognostic impact on glioblastoma is dependent on therapeutic
modalities. J Neurooncol 83: 173-179, 2007.
33. Eoli M, Menghi F, Bruzzone MG, et al: Methylation of O6-
methylguanine DNA methyltransferase and loss of hetero-
zygosity on 19q and/or 17p are overlapping features of secondary
glioblastomas with prolonged survival. Clin Cancer Res 13:
2606-2613, 2007.
34. Brandes AA, Tosoni A, Franceschi E, et al: Recurrence pattern
after temozolomide concomitant with and adjuvant to radio-
therapy in newly diagnosed patients with glioblastoma:
correlation with MGMT promoter methylation status. J Clin
Oncol 27: 1275-1279, 2009.
35. Gorlia T, van den Bent MJ, Hegi ME, et al: Nomograms for
predicting survival of patients with newly diagnosed glio-
blastoma: prognostic factor analysis of EORTC and NCIC trial
26981-22981/CE.3. Lancet Oncol 9: 29-38, 2008.
36. Wemmert S, Bettscheider M, Alt S, et al: p15 promoter
methylation - A novel prognostic marker in glioblastoma
patients. Int J Oncol 34: 1743-1748, 2009.
37. Prados MD, Chang SM, Butowski N, et al: Phase II study of
erlotinib plus temozolomide during and after radiation therapy
in patients with newly diagnosed glioblastoma multiforme or
gliosarcoma. J Clin Oncol 27: 579-584, 2009.
38. Glas M, Happold C, Rieger J, et al: Long-term survival of
patients with glioblastoma treated with radiotherapy and
lomustine plus temozolomide. J Clin Oncol 27: 1257-1261,
2009.
39. Murat A, Migliavacca E, Gorlia T, et al: Stem cell-related ‘self-
renewal’ signature and high epidermal growth factor receptor
expression associated with resistance to concomitant chemo-
radiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024, 2008.
40. Donson AM, Addo-Yobo SO, Handler MH, Gore L and
Foreman NK: MGMT promoter methylation correlates with
survival benefit and sensitivity to temozolomide in pediatric
glioblastoma. Pediatr Blood Cancer 48: 403-407, 2007.
41. Piccirilli M, Bistazzoni S, Gagliardi FM, et al: Treatment of
glioblastoma multiforme in elderly patients. Clinico-therapeutic
remarks in 22 patients older than 80 years. Tumori 92: 98-103,
2006.
42. Brandes AA, Tosoni A, Cavallo G, et al: Temozolomide 3
weeks on and 1 week off as first-line therapy for recurrent
glioblastoma: phase II study from Gruppo Italiano Cooperativo
di Neuro-oncologia (GICNO). Br J Cancer 95: 1155-1160,
2006.
43. Schaich M, Kestel L, Pfirrmann M, et al: A MDR1 (ABCB1)
gene single nucleotide polymorphism predicts outcome of
temozolomide treatment in glioblastoma patients. Ann Oncol
20: 175-181, 2009.
44. Dunn J, Baborie A, Alam F, et al: Extent of MGMT promoter
methylation correlates with outcome in glioblastomas given
temozolomide and radiotherapy. Br J Cancer 101: 124-131, 2009.
ONCOLOGY REPORTS  23:  1655-1662,  2010 1661
1655-1662.qxd  23/4/2010  10:20 Ì  ™ÂÏ›‰·1661
45. Brandes AA, Franceschi E, Tosoni A, et al: MGMT promoter
methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly
diagnosed glioblastoma patients. J Clin Oncol 26: 2192-2197,
2008.
46. Clarke JL, Iwamoto FM, Sul J, et al: Randomized phase II trial
of chemoradiotherapy followed by either dose-dense or metro-
nomic temozolomide for newly diagnosed glioblastoma. J Clin
Oncol 27: 3861-3867, 2009.
47. Park CK, Park SH, Lee SH, et al: Methylation status of the
MGMT gene promoter fails to predict the clinical outcome of
glioblastoma patients treated with ACNU plus cisplatin.
Neuropathology 29: 443-449, 2009.
48. Smith KA, Ashby LS, Gonzalez F, et al: Prospective trial of
gross-total resection with Gliadel wafers followed by early post-
operative gamma knife radiosurgery and conformal fractionated
radiotherapy as the initial treatment for patients with radio-
graphically suspected, newly diagnosed glioblastoma multiforme.
J Neurosurg 109 (Suppl): 106-117, 2008.
49. Sadones J, Michotte A, Veld P, et al: MGMT promoter hyper-
methylation correlates with a survival benefit from temozolo-
mide in patients with recurrent anaplastic astrocytoma but not
glioblastoma. Eur J Cancer 45: 146-153, 2009.
50. Sijben AE, McIntyre JB, Roldan GB, et al: Toxicity from
chemoradiotherapy in older patients with glioblastoma
multiforme. J Neurooncol 89: 97-103, 2008.
51. Metellus P, Coulibaly B, Nanni I, et al: Prognostic impact of
O(6)-methylguanine-DNA methyltransferase silencing in
patients with recurrent glioblastoma multiforme who undergo
surgery and carmustine wafer implantation: a prospective
patient cohort. Cancer 115: 4783-4794, 2009.
52. Grossman SA, Ye X, Chamberlain M, et al: Talampanel with
standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. J Clin
Oncol 27: 4155-4161, 2009.
53. Martinez R, Martin-Subero JI, Rohde V, et al: A microarray-
based DNA methylation study of glioblastoma multiforme.
Epigenetics 4: 255-264, 2009.
54. Piperi C, Themistocleous MS, Papavassiliou GA, et al: High
incidence of MGMT and RARbeta promoter methylation in
primary glioblastomas: association with histopathological
characteristics, inflammatory mediators and clinical outcome.
Mol Med 16: 1-9, 2009.
55. Weller M, Felsberg J, Hartmann C, et al: Molecular predictors
of progression-free and overall survival in patients with newly
diagnosed glioblastoma: A prospective translational study of the
German Glioma Network. J Clin Oncol 27: 5743-5750, 2009.
56. Yachi K, Watanabe T, Ohta T, et al: Relevance of MSP assay
for the detection of MGMT promoter hypermethylation in
glioblastomas. Int J Oncol 33: 469-475, 2008.
57. Shen L, Guo Y, Chen X, Ahmed S and Issa JP: Optimizing
annealing temperature overcomes bias in bisulfite PCR methy-
lation analysis. Biotechniques 42: 48, 50, 52, passim, 2007.
58. Kagan J, Srivastava S, Barker PE, Belinsky SA and Cairns P:
Towards clinical application of methylated DNA sequences as
cancer biomarkers: A Joint NCI's EDRN and NIST Workshop
on Standards, Methods, Assays, Reagents and Tools. Cancer
Res 67: 4545-4549, 2007.
59. Vlassenbroeck I, Califice S, Diserens AC, et al: Validation of
real-time methylation-specific PCR to determine O6-methyl-
guanine-DNA methyltransferase gene promoter methylation in
glioma. J Mol Diagn 10: 332-337, 2008.
60. Kitange GJ, Carlson BL, Mladek AC, et al: Evaluation of
MGMT promoter methylation status and correlation with
temozolomide response in orthotopic glioblastoma xenograft
model. J Neurooncol 92: 23-31, 2009.
61. Parrella P, la Torre A, Copetti M, et al: High specificity of
quantitative methylation-specific PCR analysis for MGMT
promoter hypermethylation detection in gliomas. J Biomed
Biotechnol 2009: 531692, 2009.
62. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS and
Futscher BW: Methylation of discrete regions of the O6-
methylguanine DNA methyltransferase (MGMT) CpG island
is associated with heterochromatinization of the MGMT
transcription start site and silencing of the gene. Mol Cell Biol
17: 5612-5619, 1997.
63. Everhard S, Tost J, El Abdalaoui H, et al: Identification of
regions correlating MGMT promoter methylation and gene
expression in glioblastomas. Neuro Oncol 11: 348-356, 2009.
64. Costello JF, Futscher BW, Kroes RA and Pieper RO:
Methylation-related chromatin structure is associated with
exclusion of transcription factors from and suppressed expression
of the O-6-methylguanine DNA methyltransferase gene in
human glioma cell lines. Mol Cell Biol 14: 6515-6521, 1994.
65. Blough MD, Zlatescu MC and Cairncross JG: O6-methyl-
guanine-DNA methyltransferase regulation by p53 in astrocytic
cells. Cancer Res 67: 580-584, 2007.
66. Danam RP, Howell SR, Brent TP and Harris LC: Epigenetic
regulation of O6-methylguanine-DNA methyltransferase gene
expression by histone acetylation and methyl-CpG binding
proteins. Mol Cancer Ther 4: 61-69, 2005.
67. Nakagawachi T, Soejima H, Urano T, et al: Silencing effect of
CpG island hypermethylation and histone modifications on O6-
methylguanine-DNA methyltransferase (MGMT) gene
expression in human cancer. Oncogene 22: 8835-8844, 2003.
68. Zhao W, Soejima H, Higashimoto K, et al: The essential role of
histone H3 Lys9 di-methylation and MeCP2 binding in MGMT
silencing with poor DNA methylation of the promoter CpG
island. J Biochem 137: 431-440, 2005.
69. Natsume A, Ishii D, Wakabayashi T, et al: IFN-beta down-
regulates the expression of DNA repair gene MGMT and
sensitizes resistant glioma cells to temozolomide. Cancer Res
65: 7573-7579, 2005.
70. Parkinson JF, Wheeler HR, Clarkson A, et al: Variation of O(6)-
methylguanine-DNA methyltransferase (MGMT) promoter
methylation in serial samples in glioblastoma. J Neurooncol 87:
71-78, 2008.
71. Wick W, Platten M and Weller M: New (alternative) temozo-
lomide regimens for the treatment of glioma. Neuro Oncol 11:
69-79, 2009.
72. Friedman HS: Can O6-alkylguanine-DNA alkyltransferase
depletion enhance alkylator activity in the clinic? Clin Cancer
Res 6: 2967-2968, 2000.
73. Quinn JA, Desjardins A, Weingart J, et al: Phase I trial of
temozolomide plus O6-benzylguanine for patients with recurrent
or progressive malignant glioma. J Clin Oncol 23: 7178-7187,
2005.
74. Spiro TP, Gerson SL, Liu L, et al: O6-benzylguanine: a clinical
trial establishing the biochemical modulatory dose in tumor
tissue for alkyltransferase-directed DNA repair. Cancer Res 59:
2402-2410, 1999.
75. Tolcher AW, Gerson SL, Denis L, et al: Marked inactivation of
O6-alkylguanine-DNA alkyltransferase activity with protracted
temozolomide schedules. Br J Cancer 88: 1004-1011, 2003.
COSTA et al:  MGMT PROMOTER METHYLATION AND OUTCOME OF GLIOBLASTOMA PATIENTS1662
1655-1662.qxd  23/4/2010  10:20 Ì  ™ÂÏ›‰·1662
